Viridian Therapeutics Inc has a consensus price target of $38.63, established from looking at the 53 latest analyst ratings. The last 3 analyst ratings were released from B. Riley Securities, Needham, and HC Wainwright & Co. on March 21, 2024, March 20, 2024, and February 29, 2024. With an average price target of $30.67 between B. Riley Securities, Needham, and HC Wainwright & Co., there's an implied 75.14% upside for Viridian Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/21/2024 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 42.78% | B. Riley Securities | Kalpit Patel | $29 → $25 | Maintains | Buy | Get Alert |
03/20/2024 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 71.33% | Needham | Serge Belanger | $30 → $30 | Maintains | Buy | Get Alert |
02/29/2024 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 111.31% | HC Wainwright & Co. | Douglas Tsao | → $37 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 128.44% | Wedbush | Laura Chico | $39 → $40 | Maintains | Outperform | Get Alert |
02/28/2024 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 71.33% | Needham | Serge Belanger | → $30 | Reiterates | Buy → Buy | Get Alert |
12/19/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 105.6% | Oppenheimer | Leland Gershell | $35 → $36 | Maintains | Outperform | Get Alert |
12/18/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 111.31% | HC Wainwright & Co. | Douglas Tsao | → $37 | Reiterates | Buy → Buy | Get Alert |
12/14/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 99.89% | RBC Capital | Gregory Renza | → $35 | Reiterates | Outperform → Outperform | Get Alert |
12/04/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 111.31% | Wedbush | Laura Chico | → $37 | Reiterates | Outperform → Outperform | Get Alert |
11/14/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 99.89% | RBC Capital | Gregory Renza | → $35 | Reiterates | Outperform → Outperform | Get Alert |
11/14/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 117.02% | JMP Securities | Jason Butler | $42 → $38 | Maintains | Market Outperform | Get Alert |
10/31/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 99.89% | RBC Capital | Gregory Renza | $44 → $35 | Maintains | Outperform | Get Alert |
10/31/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 111.31% | Wedbush | Laura Chico | $46 → $37 | Maintains | Outperform | Get Alert |
10/30/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 71.33% | Needham | Serge Belanger | $40 → $30 | Maintains | Buy | Get Alert |
09/13/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 128.44% | Stifel | Alex Thompson | → $40 | Reiterates | Buy → Buy | Get Alert |
09/13/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 162.71% | Wedbush | Laura Chico | → $46 | Reiterates | Outperform → Outperform | Get Alert |
08/10/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 111.31% | HC Wainwright & Co. | Douglas Tsao | $40 → $37 | Maintains | Buy | Get Alert |
08/10/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 128.44% | Needham | Serge Belanger | $47 → $40 | Maintains | Buy | Get Alert |
08/09/2023 | VRDN | Buy Now | Viridian Therapeutics | $17.51 | 139.86% | JMP Securities | Jason Butler | $44 → $42 | Maintains | Market Outperform | Get Alert |
The latest price target for Viridian Therapeutics (NASDAQ: VRDN) was reported by B. Riley Securities on March 21, 2024. The analyst firm set a price target for $25.00 expecting VRDN to rise to within 12 months (a possible 42.78% upside). 38 analyst firms have reported ratings in the last year.
The latest analyst rating for Viridian Therapeutics (NASDAQ: VRDN) was provided by B. Riley Securities, and Viridian Therapeutics maintained their buy rating.
There is no last upgrade for Viridian Therapeutics.
There is no last downgrade for Viridian Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.
While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a maintained with a price target of $29.00 to $25.00. The current price Viridian Therapeutics (VRDN) is trading at is $17.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.